Frida Hjelmberg - Ziccum AB Chief Officer

ZICC Stock

SEK 0.25 0.14 35.90%

Insider

Frida Hjelmberg is Chief Officer of Ziccum AB

Age	39
Phone	46 7 09 61 55 99
Web	https://ziccum.com

Ziccum AB Management Efficiency

The company has return on total asset (ROA) of (0.5157) % which means that it has lost $0.5157 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.9753) %, meaning that it generated substantial loss on money invested by shareholders. Ziccum AB's management efficiency ratios could be used to measure how well Ziccum AB manages its routine affairs as well as how well it operates its assets and liabilities.

Compare Ziccum AB to Peers

Predict price of Ziccum AB

Ziccum AB has accumulated 1.43 M in total debt with debt to equity ratio (D/E) of 0.06, which may suggest the company is not taking enough advantage from borrowing. Ziccum AB has a current ratio of 9.43, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Ziccum AB until it has trouble settling it off, either with new capital or with free cash flow. So, Ziccum AB's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Ziccum AB sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Ziccum to invest in growth at high rates of return. When we think about Ziccum AB's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives			INSIDER Age
	Lars Levin	C Rad AB	52
	Maria Edholm	Genovis AB	N/A
	Magnus Langberg	Genovis AB	52
	Xiaodong Wang	C Rad AB	44
	Fredrik Olsson	Genovis AB	52
	Ivan Astralaga	C Rad AB	N/A
	Associate Gier	Xbrane Biopharma AB	N/A
	David Vikstrm	Xbrane Biopharma AB	46
	Rikke Rytter	Genovis AB	56
	Erik Domines	Xbrane Biopharma AB	59
	Maria Edebrink	Xbrane Biopharma AB	54
	Adnan Deronic	Cantargia AB	N/A
	Ignacio GarciaRibas	Cantargia AB	N/A
	Patrik Hellberg	Intervacc AB	N/A
	Nina Ivers	Xbrane Biopharma AB	53
	Kjell Sjstrm	Cantargia AB	N/A
	Thoas MD	Cantargia AB	61
	Peter Madsen	Cantargia AB	N/A
	Hakan Axelsson	C Rad AB	55
	Samuel Wagner	Xbrane Biopharma AB	N/A
	Andrew Waller	Intervacc AB	N/A

Ziccum AB develops dry powder preparations of biological pharmaceuticals. The company was founded in 2017 and is headquartered in Lund, Sweden. Ziccum AB is traded on Stockholm Stock Exchange in Sweden. Ziccum AB (ZICC) is traded on Stockholm Exchange in Sweden and employs 3 people.

Management Performance

	Return On Equity	-0.98
	Return On Asset	-0.52

Ziccum AB Management Team

Elected by the shareholders, the Ziccum AB's board of directors comprises two types of representatives: Ziccum AB inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ziccum. The board's role is to monitor Ziccum AB's management team and ensure that shareholders' interests are well served. Ziccum AB's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ziccum AB's outside directors are responsible for providing unbiased perspectives on the board's policies.

	Frida Hjelmberg, Chief Officer
	Fabrice Rose, Scientific Director
	Ann Gidner, Chief Officer

Ziccum Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ziccum AB a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

	Return On Equity	-0.98
	Return On Asset	-0.52
	Current Valuation	2.01 M
	Shares Outstanding	13.81 M
	Shares Owned By Insiders	25.53 %
	Price To Book	0.81 X
	Price To Sales	2,383 X
	Gross Profit	17 K
	EBITDA	(20.27 M)
	Net Income	(21.14 M)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Ziccum Stock Analysis

When running Ziccum AB's price analysis, check to measure Ziccum AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ziccum AB is operating at the current time. Most of Ziccum AB's value examination focuses on studying past and present price action to predict the probability of Ziccum AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ziccum AB's price. Additionally, you may evaluate how the addition of Ziccum AB to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC